Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-838 in Relapsed and Refractory Multiple Myeloma
NCT02462525Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 1, open-label trial of azintuxizumab vedotin in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum plasma concentration and Maximum Tolerated Dose up to 2 years. Started May 2015; status: terminated.
02
Drugs
azintuxizumab vedotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02462525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462525.